SCPC’s Comment Letter on the Request for Information Regarding Reporting on Pharmacy Benefit and Prescription Drug Costs

Today, the Senior Care Pharmacy Coalition (SCPC) responded to questions on data collection impacting PBMs and prescription drug costs. First, SCPC urges the Biden Administration to define long-term care (LTC) pharmacies distinctly from other pharmacies (e.g., retail, mail order, and specialty). In addition, the coalition strongly recommends the new regulation collect information on rebates, fees, and other direct and indirect renumeration (DIR)—creating more transparency into the exchanges between key entities that drive up prescription drug costs. Namely, collecting data between health insurance plans, their Pharmacy Benefit Managers (PBMs), drug manufacturers, and pharmacies. Collecting and publicizing this information will support a broader investigation into the anti-competitive practices of major companies.

Read the full letter here.